This is the first in a two-part series that examines how--or whether--drug companies and the US Food and Drug Administration can use microarray data in the drug-approval process. Today's installment covers whether microarray technology has a place in the later stages of drug development, while tomorrow's article will explore how the FDA and pharma firms plan to usher the technology into the mainstream.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.